Methylphenidate Transdermal Articles

Shire agrees to settlement with US government over ADHD drug marketing

4 February 2013

Global ADHD market set to grow at a CAGR of 8% to 2018

14 December 2011

Shire divests ADHD drug Daytrana to Noven Pharma; says 2010 earnings outlook unchanged

11 August 2010

EMEA recommends Replagal as alternative Fabry treatment due to Fabrazyme shortage; FDA approves Shire’s Daytrana for adolescents

7 July 2010

Shire recalls 39 lots of Daytrana due to design flaws

30 March 2009

Shire withdaws EU Daytrana MAA

23 March 2009

Shire's Vyvanse projected to gain blockbuster status by 2017

13 October 2008

Noven gets final $25M Shire milestone

11 August 2008

Shire orders limited recall of Daytrana patch

10 September 2007

Shire's 3rd-qtr 2006 revenue rises 19%

6 November 2006

Shire's net income improves 75% in 1st qtr

8 May 2006

Noven's Daytrana gets FDA go-ahead for ADHD

17 April 2006

Noven to start making Daytrana

19 December 2005

FDA: Shire's Daytrana safe and effective

12 December 2005

Shire and Noven resubmit MTS for pediatric ADHD

1 August 2005

Shire provides key R&D candidates update

16 May 2005

Positive data for Shire/Noven's ADHD drug

18 April 2005

Noven gains $25M from Shire

14 April 2003

Showing 1-18 of 18 articles

Go to beginningPrevious
  • 1
NextGo to end